XML 33 R22.htm IDEA: XBRL DOCUMENT
v3.20.4

Stockholders' Equity (Deficit) | 9 Months Ended
--- | ---
Dec. 31, 2020
Equity [Abstract] |
Stockholders' Equity (Deficit) | Stockholders' Equity (Deficit) Each share of the Company’s outstanding common stock is permitted one vote on proposals presented to stockholders and is entitled to share equally in any dividends declared by the Company’s Board of Directors (the “Board”). On July 29, 2020, the Company raised its quarterly dividend from $0.41 to $0.42 per common share for dividends declared on or after such date by the Board. The Company anticipates that it will continue to pay quarterly cash dividends in the future. However, the payment and amount of future dividends remain within the discretion of the Board and will depend upon the Company's future earnings, financial condition, capital requirements, and other factors. Share Repurchase Plans Stock repurchases may be made from time to time in open market transactions, privately negotiated transactions, through accelerated share repurchase (“ASR”) programs, or by combinations of such methods, any of which may use pre-arranged trading plans that are designed to meet the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934. The timing of any repurchases and the actual number of shares repurchased will depend on a variety of factors, including the Company’s stock price, corporate and regulatory requirements, restrictions under the Company’s debt obligations, and other market and economic conditions. During the three months ended June 30, 2020, there were no share repurchases made under previously authorized share repurchase programs. During the three months ended September 30, 2020, the Company repurchased 1.8 million of the Company’s shares for $269 million through open market transactions at an average price per share of $151.23. During the three months ended December 31, 2020, the Company repurchased 1.5 million of the Company’s shares for $231 million through open market transactions at an average price per share of $151.12. The total authorization outstanding for repurchases of the Company’s common stock was $1.0 billion at December 31, 2020. In January 2021, the Board approved an increase of $2.0 billion for the authorized share repurchase of McKesson’s common stock. Other Comprehensive Income (Loss) Information regarding Other comprehensive income (loss) including noncontrolling interests and redeemable noncontrolling interests, net of tax, by component is as follows:
| Three Months Ended December 31, |  | Nine Months Ended December 31,
(In millions) | 2020 |  | 2019 |  | 2020 |  | 2019 |
Foreign currency translation adjustments (1) |  |  |  |  |  |  |  |
Foreign currency translation adjustments arising during period, net of income tax expense of nil, nil, nil, and nil (2) (3) | $ | 156 |  |  | $ | 101 |  |  | $ | 363 |  |  | $ | 57 |  |
Reclassified to income statement, net of income tax expense of nil, nil, nil, and nil (4) | 47 |  |  | — |  |  | 47 |  |  | — |  |
| 203 |  |  | 101 |  |  | 410 |  |  | 57 |  |
Unrealized losses on net investment hedges |  |  |  |  |  |  |  |
Unrealized losses on net investment hedges arising during period, net of income tax benefit of $33, $21, $80, and $1 (3)(5) | (96) |  |  | (58) |  |  | (229) |  |  | (2) |  |
Reclassified to income statement, net of income tax expense of nil, nil, nil, and nil | — |  |  | — |  |  | — |  |  | — |  |
| (96) |  |  | (58) |  |  | (229) |  |  | (2) |  |
Unrealized gains (losses) on cash flow hedges |  |  |  |  |  |  |  |
Unrealized gains (losses) on cash flow hedges arising during period, net of income tax (expense) benefit of $2, $3, $6, and $(7) | (12) |  |  | 8 |  |  | (36) |  |  | 33 |  |
Reclassified to income statement, net of income tax expense of nil, nil, nil, and nil | — |  |  | — |  |  | — |  |  | — |  |
| (12) |  |  | 8 |  |  | (36) |  |  | 33 |  |
Changes in retirement-related benefit plans (6) |  |  |  |  |  |  |  |
Net actuarial loss and prior service cost arising during the period, net of income tax benefit of nil, nil, nil, and $1 | — |  |  | — |  |  | — |  |  | (3) |  |
Amortization of actuarial loss, prior service cost and transition obligation, net of income tax benefit of $2, nil, $1, and nil (7) | (2) |  |  | (2) |  |  | — |  |  | — |  |
Foreign currency translation adjustments and other, net of income tax expense of nil, nil, nil, and nil (4) | 2 |  |  | (6) |  |  | (8) |  |  | 1 |  |
Reclassified to income statement, net of income tax expense of $9, $3, $9, and $35 (8) | 24 |  |  | 8 |  |  | 24 |  |  | 98 |  |
| 24 |  |  | — |  |  | 16 |  |  | 96 |  |
Other comprehensive income, net of tax | $ | 119 |  |  | $ | 51 |  |  | $ | 161 |  |  | $ | 184 |  |
(1)Foreign currency translation adjustments primarily result from the conversion of non-U.S. dollar financial statements of the Company’s foreign subsidiary, McKesson Europe, and its operations in Canada into the Company’s reporting currency, U.S. dollars. (2)During the three and nine months ended December 31, 2020, net foreign currency translation adjustments were primarily due to the strengthening of the Canadian dollar and Euro against the U.S. dollar from April 1, 2020 to December 31, 2020. During the three and nine months ended December 31, 2019, the net foreign currency translation adjustments were primarily due to the strengthening of the Euro and Canadian dollar against the U.S. dollar, partially offset by weakening of the British pound sterling from April 1, 2019 to December 31, 2019. (3)The three and nine months ended December 31, 2020 includes net foreign currency translation adjustments of $20 million and $(41) million, respectively, and the three and nine months ended December 31, 2019 includes net foreign currency translation adjustments of $12 million and $(1) million, respectively, attributable to redeemable noncontrolling interests. (4)The three and nine months ended December 31, 2020 include adjustments for amounts related to the contribution of the Company’s German pharmaceutical wholesale business to a joint venture, as discussed in more detail in Financial Note 3, “Held for Sale.” These amounts were included in the current and prior periods calculation of charges to remeasure the assets and liabilities held for sale to fair value less costs to sell recorded within Operating expenses in the Condensed Consolidated Statements of Operations. (5)The three and nine months ended December 31, 2020 includes foreign currency losses of $84 million and $201 million, respectively, on the net investment hedges from the €1.7 billion Euro-denominated notes and £450 million British pound sterling-denominated notes, losses of $45 million and $108 million, respectively, on the net investment hedges from cross-currency swaps, and losses on net investment hedges of nil and $1 million, respectively, attributable to redeemable noncontrolling interests. The three and nine months ended December 31, 2019 include foreign currency losses of $59 million and gains of $8 million, respectively, on the net investment hedges from the €1.70 billion Euro-denominated notes and £450 million British pound sterling-denominated notes and losses of $20 million and $11 million, respectively, on the net investment hedges from cross-currency swaps. (6)The three and nine months ended December 31, 2020 include net actuarial gains of $5 million and $3 million, respectively, and the three and nine months ended December 31, 2019 include net actuarial losses of $2 million and $1 million, respectively, which are attributable to redeemable noncontrolling interests. (7)Pre-tax amount was reclassified into Cost of sales and Operating expenses in the Condensed Consolidated Statements of Operations. The related tax expense was reclassified into Income tax benefit (expense) in the Condensed Consolidated Statements of Operations. (8)The nine months ended December 31, 2019 primarily reflects a reclassification of losses in the second quarter of 2020 upon a pension settlement charge from Accumulated other comprehensive loss to Other income (expense), net in the Condensed Consolidated Statement of Operations. Accumulated Other Comprehensive Income (Loss) Information regarding changes in the Company’s Accumulated other comprehensive income (loss) by component for the three and nine months ended December 31, 2020 are as follows:
| Foreign Currency Translation Adjustments |  |  |  |  |  |
(In millions) | Foreign Currency Translation Adjustments, Net of Tax |  | Unrealized Gains (Losses) on Net Investment Hedges, Net of Tax |  | Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax |  | Unrealized Net Losses and Other Components of Benefit Plans, Net of Tax |  | Total Accumulated Other Comprehensive Loss
Balance at September 30, 2020 | $ | (1,512) |  |  | $ | 6 |  |  | $ | 25 |  |  | $ | (116) |  |  | $ | (1,597) |
Other comprehensive income (loss) before reclassifications | 156 |  |  | (96) |  |  | (12) |  |  | 2 |  |  | 50 |
Amounts reclassified to earnings and other | 47 |  |  | — |  |  | — |  |  | 22 |  |  | 69 |
Other comprehensive income (loss) | 203 |  |  | (96) |  |  | (12) |  |  | 24 |  |  | 119 |
Less: amounts attributable to noncontrolling and redeemable noncontrolling interests | 20 |  |  | — |  |  | — |  |  | 5 |  |  | 25 |
Other comprehensive income (loss) attributable to McKesson | 183 |  |  | (96) |  |  | (12) |  |  | 19 |  |  | 94 |
Balance at December 31, 2020 | $ | (1,329) |  |  | $ | (90) |  |  | $ | 13 |  |  | $ | (97) |  |  | $ | (1,503) |
| Foreign Currency Translation Adjustments |  |  |  |  |  |
(In millions) | Foreign Currency Translation Adjustments, Net of Tax |  | Unrealized Gains (Losses) on Net Investment Hedges, Net of Tax |  | Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax |  | Unrealized Net Gains (Losses) and Other Components of Benefit Plans, Net of Tax |  | Total Accumulated Other Comprehensive Loss
Balance at March 31, 2020 | $ | (1,780) |  |  | $ | 138 |  |  | $ | 49 |  |  | $ | (110) |  |  | $ | (1,703) |
Other comprehensive income (loss) before reclassifications | 363 |  |  | (229) |  |  | (36) |  |  | (8) |  |  | 90 |
Amounts reclassified to earnings and other | 47 |  |  | — |  |  | — |  |  | 24 |  |  | 71 |
Other comprehensive income (loss) | 410 |  |  | (229) |  |  | (36) |  |  | 16 |  |  | 161 |
Less: amounts attributable to noncontrolling and redeemable noncontrolling interests | (41) |  |  | (1) |  |  | — |  |  | 3 |  |  | (39) |
Other comprehensive income (loss) attributable to McKesson | 451 |  |  | (228) |  |  | (36) |  |  | 13 |  |  | 200 |
Balance at December 31, 2020 | $ | (1,329) |  |  | $ | (90) |  |  | $ | 13 |  |  | $ | (97) |  |  | $ | (1,503) |
Information regarding changes in the Company’s Accumulated other comprehensive income (loss) by component for the three and nine months ended December 31, 2019 are as follows:
| Foreign Currency Translation Adjustments |  |  |  |  |  |
(In millions) | Foreign Currency Translation Adjustments, Net of Tax |  | Unrealized Gains (Losses) on Net Investment Hedges, Net of Tax |  | Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax |  | Unrealized Net Gains (Losses) and Other Components of Benefit Plans, Net of Tax |  | Total Accumulated Other Comprehensive Loss
Balance at September 30, 2019 | $ | (1,659) |  |  | $ | 109 |  |  | $ | (12) |  |  | $ | (142) |  |  | $ | (1,704) |
Other comprehensive income (loss) before reclassifications | 101 |  |  | (58) |  |  | 8 |  |  | (6) |  |  | 45 |
Amounts reclassified to earnings and other | — |  |  | — |  |  | — |  |  | 6 |  |  | 6 |
Other comprehensive income (loss) | 101 |  |  | (58) |  |  | 8 |  |  | — |  |  | 51 |
Less: amounts attributable to noncontrolling and redeemable noncontrolling interests | 12 |  |  | — |  |  | — |  |  | (2) |  |  | 10 |
Other comprehensive income (loss) attributable to McKesson | 89 |  |  | (58) |  |  | 8 |  |  | 2 |  |  | 41 |
Balance at December 31, 2019 | $ | (1,570) |  |  | $ | 51 |  |  | $ | (4) |  |  | $ | (140) |  |  | $ | (1,663) |
| Foreign Currency Translation Adjustments |  |  |  |  |  |
(In millions) | Foreign Currency Translation Adjustments, Net of Tax |  | Unrealized Gains (Losses) on Net Investment Hedges, Net of Tax |  | Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax |  | Unrealized Net Gains (Losses) and Other Components of Benefit Plans, Net of Tax |  | Total Accumulated Other Comprehensive Loss
Balance at March 31, 2019 | $ | (1,628) |  |  | $ | 53 |  |  | $ | (37) |  |  | $ | (237) |  |  | $ | (1,849) |
Other comprehensive income (loss) before reclassifications | 57 |  |  | (2) |  |  | 33 |  |  | (2) |  |  | 86 |
Amounts reclassified to earnings and other | — |  |  | — |  |  | — |  |  | 98 |  |  | 98 |
Other comprehensive income (loss) | 57 |  |  | (2) |  |  | 33 |  |  | 96 |  |  | 184 |
Less: amounts attributable to noncontrolling and redeemable noncontrolling interests | (1) |  |  | — |  |  | — |  |  | (1) |  |  | (2) |
Other comprehensive income (loss) attributable to McKesson | 58 |  |  | (2) |  |  | 33 |  |  | 97 |  |  | 186 |
Balance at December 31, 2019 | $ | (1,570) |  |  | $ | 51 |  |  | $ | (4) |  |  | $ | (140) |  |  | $ | (1,663) |

X
- References No definition available. + Details
Name: | us-gaap_EquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -URI http://asc.fasb.org/topic&trid=2208762 + Details
Name: | us-gaap_StockholdersEquityNoteDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration